{'fraction_non_alphanumeric': 0.0213089802130898, 'fraction_numerical': 0.015220700152207, 'mean_word_length': 4.950226244343892, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Tolerance and long-term efficacy of a fixed combination of atenolol and nifedipine in the treatment of angina pectoris. Stuart Clinical Research Group.

To monitor the tolerance and long-term efficacy of a low-dose fixed combination of 50 mg atenolol and 20 mg nifedipine (slow release formulation) in patients with stable angina pectoris, 157 patients received treatment twice daily in a multi-centre, open-label fashion for periods up to 12 months following a four week run-in period on atenolol 50 mg twice daily. A total of 122 patients completed the study and had data from all treatment visits. In these patients the median number of weekly anginal attacks was halved, compared to the run-in period on atenolol alone following one month's fixed combination treatment, and this benefit was maintained throughout the 12-month study period. In addition, GTN consumption similarly declined on the fixed combination in comparison with the run-in period. Treatment with the fixed combination was not associated with any long-term increase in the frequency of reported side-effects or adverse biochemical changes compared to run-in. The fixed combination of atenolol 50 mg and nifedipine 20 mg reduced anginal frequency and GTN consumption compared to atenolol alone without causing any increase in adverse effects.